



Amendments to the Claims


1. (Currently Amended) A compound of formula (I):-



such that Ar is an aryl or a heteroaryl, and the
the aryl,
wherein:-



is beta to the



on

----- is a single or a double bond;

R¹ and R² are each independently hydrogen or lower alkyl;

R³ is aryl, arylalkenyl, cycloalkenyl, cycloalkyl, heteroaryl, heteroarylalkenyl, heterocycloalkenyl, a carbon linked heterocycloalkyl or alkyl optionally substituted by one or more groups selected from hydroxy, alkoxy, alkyloxycarbonylamino, cycloalkyl, heterocycloalkyl, R⁶, -OR⁶, -S(O)_mR⁶ or -C(=O)-R⁶;

R⁴ is hydrogen, acyl, alkoxy, alkyloxycarbonyl, carboxy, cyano, halo, hydroxy, -C(=O)-NY¹Y² or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, hydroxy, -S(O)_m-alkyl or -NY¹Y²;

R⁶ is aryl or heteroaryl;

Y¹ and Y² are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl or heterocycloalkyl; or the group -NY¹Y² may form a cyclic amine;

m is zero or an integer 1 to 2; and

n is ~~2~~ zero or an integer ~~1~~ to 4; or


an N-oxide of said compound, a prodrug of said compound, a pharmaceutically acceptable salt of said compound, a solvate of said compound, or a hydrate of said compound.

2. (Currently Amended) The compound of Claim 1, wherein R^1 or R^2 is hydrogen, or R^1 and R^2 are hydrogen, and R^3 is an aryl or an a heteroaryl.
3. (Previously Presented) The compound of Claim 2, wherein said R^3 is a phenyl or a naphthyl.
4. (Previously Presented) The compound of Claim 2, wherein said R^3 is aryl substituted with at least one substituent.
5. (Original) The compound of Claim 4, wherein said substituent is selected from the group consisting of a halo atom, an alkyl substituted by aryl, an alkyl substituted by aryloxy, an alkyl substituted by aroyl, an alkyl substituted by heteroaryl, an arylalkynyl, a heteroarylalkynyl, an aryl, a heteroaryl, an arylalkenyl and an arylalkyloxy.
6. (Original) The compound of Claim 5, wherein said aryl or heteroaryl of said substituent is further substituted by at least one aryl group substituent.
7. (Previously Presented) The compound of Claim 2, wherein said heteroaryl is a pyridyl, a quinolinyl, a thienyl, a furanyl, or an indolyl.
8. (Original) The compound of Claim 7, wherein said heteroaryl is substituted with at least one substituent.
9. (Previously Presented) The compound of Claim 8, wherein said substituent is an alkyl, an alkyl substituted by an aryl, an alkyl substituted by an aryloxy, an alkyl substituted by an aroyl, an alkyl substituted heteroaryl, an arylalkynyl, a heteroarylalkynyl, a heteroaryl, an arylalkenyl or an arylalkyoxo.
10. (Original) The compound of Claim 9, wherein said aryl of said substituent is further substituted by at least one aryl substituent.
11. (Previously Presented) The compound of Claim 1, wherein R^4 is hydrogen or a cyano group.

12. (Previously Presented) The compound of Claim 1, wherein R^5 is a hydrogen, a lower alkyl, or a halo.
13. (Cancelled).
14. (Cancelled).
- 13 15. (Currently Amended) The compound of Claim 1, wherein:
Ar is a phenyl group;
 R^1 and R^2 are both hydrogen;
 R^3 is an aryl, a naphthyl or a heteroaryl;
 R^4 is hydrogen or a cyano; and
----- is a single bond; and
----- $n=2$.
- 14 16. (Previously Presented) The compound of Claim ¹³15, wherein R^3 as aryl or naphthyl is substituted with at least one substituent selected from the group consisting of a halo atom, an alkyl substituted by aryl, an alkyl substituted by aryloxy, an alkyl substituted by aroyl, an alkyl substituted by aryloxy, an alkyl substituted by aroyl, an alkyl substituted by a heteroaryl, an arylalkynyl, a heteroarylalkynyl, an aryl, a heteroaryl, an arylalkenyl, and an arylalkyloxy.
- 15 17. (Original) The compound of Claim ¹⁴16, wherein said aryl or said heteroaryl of said substituent is further substituted by at least one aryl substituent.
- 16 18. (Previously Presented) The compound of Claim ¹³15, wherein R^3 as heteroaryl is substituted by at least one substituent selected from the group consisting of a pyridyl, a quinolinyl, a thienyl a furanyl, ~~or~~ and an indolyl.
- 17 19. (Previously Presented) The compound of Claim ¹⁶18, wherein said substituent of said heteroaryl is further substituted by at least one moiety selected from the group consisting of an alkyl substituted by an aryl, an alkyl substituted by an aryloxy, an alkyl substituted by an aroyl, an alkyl substituted heteroaryl, an arylalkynyl, a heteroarylalkynyl, a heteroaryl, an arylalkenyl, and an arylalkyloxy.

18 20. (Original) The compound of Claim 19¹⁷, wherein an aryl of said moiety is further substituted by at least one aryl substituent.

19 21. (Currently Amended) A compound of formula (Ia):



wherein is a single or double bond;
R¹ and R² are each independently hydrogen or lower alkyl;

R³ is aryl, arylalkenyl, cycloalkenyl, cycloalkyl, heteroaryl, heteroarylalkenyl, heterocycloalkenyl, a carbon linked heterocycloalkyl or alkyl optionally substituted by one or more groups selected from hydroxy, alkoxy, alkylloxycarbonylamino, cycloalkyl, heterocycloalkyl, R⁶, -OR⁶, -S(O)_mR⁶ or -C(=O)-R⁶;

R⁴ is hydrogen, acyl, alkoxy, alkylloxycarbonyl, carboxy, cyano, halo, hydroxy, -C(=O)-NY¹Y² or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, hydroxy, -S(O)_m-alkyl or -NY¹Y²;

R⁵ is hydrogen, acyl, alkoxy, alkylloxycarbonyl, aryl, carboxy, cyano, halo, heteroaryl, heteroarylalkoxy, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylalkyloxy, heteroarylalkyloxy, hydroxy, trifluoromethyl, -C(=O)-NY¹Y², -NY¹Y²,

-Z¹-C₂₋₆alkylene-R⁷ or alkyl optionally substituted with alkoxy, alkylcarbonylamino, alkylsulfonylamino, aryl, heteroaryl, heterocycloalkyl, hydroxy, ureido, -C(=O)-NY¹Y², -SO₂-NY¹Y², -S(O)_m-alkyl or -NY¹Y², and

R⁶ is aryl or heteroaryl;

R⁷ is hydroxy, alkoxy, ureido, -C(=O)-NY¹Y², -SO₂-NY¹Y², -S(O)_m-alkyl or -NY¹Y²,

R⁸ is hydrogen or lower alkyl;

Y¹ and Y² are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl or heterocycloalkyl; or the group -NY¹Y² may form a cyclic amine;

Z¹ is O, S(O)_m or NR⁸;

m is zero or an integer 1 to 2; and

n is ~~2 zero or an integer 1 to 4~~; or

an N-oxide of said compound, a prodrug of said compound, a pharmaceutically acceptable salt of said compound, a solvate of said compound, an N-oxide of said solvate of said compound, or a prodrug of said solvate of said compound.

- 20 22. (Previously Presented) The compound of Claim ¹⁹21, wherein R³ is a phenyl or a naphthyl.
- 21 23. (Previously Presented) The compound of Claim ²⁰22, wherein said aryl is substituted by at least one substituent selected from the group consisting of a halo atom, an alkyl substituted by an aryl, and an alkyl substituted by a heteroaryl.
- 22 24. (Original) The compound of Claim ²¹23, wherein said aryl or heteroaryl of said substituent is further substituted by at least one aryl group substituent.
- 23 25. (Previously Presented) The compound of Claim ¹⁹21, wherein R³ is phenylC₁₋₃alkylpyridyl, phenylC₁₋₃alkylthienyl or indolyl.
- 25 26. (Previously Presented) The compound of Claim ¹⁹21, wherein R³ is a heteroaryl selected from the group consisting of a pyridyl, a quinolinyl, a thienyl, a furanyl, and an indolyl.
- 26 27. (Previously Presented) The compound of Claim ²⁵26, wherein said heteroaryl is substituted by at least one substituent selected from the group consisting of an alkyl substituted by an aryl, and an alkyl substituted by a heteroaryl.
- 27 28. (Original) The compound of Claim ²⁶27, wherein said aryl and said heteroaryl of said substituent are further substituted by at least one aryl group substituent.

28/29. (Previously Presented) The compound of Claim 28²⁷, wherein R³ is phenylC₁₋₃alkylpyridyl, phenylC₁₋₃alkylthienyl or indolyl.

30. (Previously Presented) The compound of Claim 21¹⁹, wherein R⁴ is a hydrogen or a cyano.

31. (Previously Presented) The compound of Claim 21¹⁹, wherein R⁵ is a hydrogen, a lower alkyl or a halo.

32. (Previously Presented) The compound of Claim 31, wherein R⁵ is methyl or fluoro.

33. (Original) The compound of Claim 31, wherein R⁵ is attached to the phenyl ring of formula (Ia) in the position para to the CH₂NH₂ group.

34. (Previously Presented) The compound of Claim 21¹⁹, wherein:
R³ is a phenyl, a naphthyl, a heteroaryl selected from the group consisting a pyridyl, a quinoliny, a thienyl, a furanyl, and an indolyl, a phenyl substituted by at least one substituent, a naphthyl substituted by at least one substituent, or a heteroaryl selected from the group consisting a pyridyl, a quinoliny, a thienyl, a furanyl, and an indolyl, that is substituted by at least one substituent,

wherein said substituent is selected from the group consisting of a halo atom, an alkyl substituted by aryl, and alkyl substituted heteroaryl, wherein the aryl or heteroaryl groups are further substituted by one or more aryl group substituents;

R⁴ is hydrogen or a cyano; and

R⁵ is hydrogen, a lower alkyl or a halo.


35. (Previously Presented) The compound of Claim 34, wherein:

R³ is phenylC₁₋₃alkylpyridyl, phenylC₁₋₃alkylthienyl or indolyl;

R⁴ is a hydrogen or a cyano; and

R⁵ is a methyl or a fluoro, and is attached to the phenyl ring of formula (Ia) in the position para to the CR¹R²NH₂ group.

37/36. (Previously Presented) The compound of Claim 21¹⁹, having formula (Ib):



- 38 37. (Previously Presented) The compound of Claim 36, wherein R^3 as is selected from the group consisting of a phenyl and a naphthyl.
- 39 38. (Previously Presented) The compound of Claim 37, wherein said aryl is substituted by at least one substituent selected from the group consisting of a halo atom, an alkyl substituted by an aryl, and an alkyl substituted by a heteroaryl.
- 40 39. (Original) The compound of Claim 38, wherein said aryl or heteroaryl of said substituent is further substituted by at least one aryl group substituent.
- 41 40. (Previously Presented) The compound of Claim 36, wherein R^3 is a pyridyl, a quinolinyl, a thienyl, a furanyl, or an indolyl.
- 42 41. (Previously Presented) The compound of Claim 41, wherein said heteroaryl is substituted by at least one substituent selected from the group consisting of an alkyl substituted by an aryl, or and an alkyl substituted by a heteroaryl.
- 43 42. (Original) The compound of Claim 42, wherein said aryl and said heteroaryl of said substituent are further substituted by at least one aryl group substituent.
- 44 43. (Previously Presented) The compound of Claim 36, wherein R^3 is phenylC₁₋₃alkylpyridyl, phenylC₁₋₃alkylthienyl or indolyl.
- 45 44. (Previously Presented) The compound of Claim 36, wherein R^4 is a hydrogen or a cyano.
- 46 45. (Previously Presented) The compound of Claim 36, wherein R^5 is a hydrogen, a lower alkyl or a halo.

47 46. (Previously Presented) The compound of Claim 45⁴⁶, wherein R⁵ is a methyl or a fluoro.

48 47. (Original) The compound of Claim 45⁴⁶, wherein R⁵ is attached to the phenyl ring of formula (Ib) in the position para to the CH₂NH₂ group.

49 48. (Previously Presented) The compound of Claim 36³⁷, wherein:
R³ is a phenyl, a naphthyl, a heteroaryl selected from the group consisting a pyridyl, a quinoliny, a thienyl, a furanyl, and an indolyl, a phenyl substituted by at least one substituent, a naphthyl substituted by at least one substituent, or a heteroaryl selected from the group consisting a pyridyl, a quinoliny, a thienyl, a furanyl, and an indolyl, that is substituted by at least one substituent,
wherein said substituent is selected from the group consisting of a halo atom, an alkyl substituted by aryl, and alkyl substituted heteroaryl, wherein the aryl or heteroaryl groups are further substituted by one or more aryl group substituents;

R⁴ is hydrogen or a cyano; and

R⁵ is hydrogen, a lower alkyl or a halo.

50 49. (Previously Presented) The compound of Claim 48⁴⁹, wherein:
R³ is phenylC₁₋₃alkylpyridyl, phenylC₁₋₃alkylthienyl or indolyl;
R⁴ is a hydrogen or a cyano; and
R⁵ is a methyl or a fluoro.

51 50. (Original) The compound of Claim 1, selected from the group consisting of:
3-[1-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
3-[1-(3-phenylethyl-benzoyl)-piperidin-4-yl]-benzylamine;
3-[1-[3-(4-hydroxyphenyl)ethyl-benzoyl]-piperidin-4-yl]-benzylamine;
3-[1-[3-(6-amino-pyridin-3-yl)ethyl-benzoyl]-piperidin-4-yl]-benzylamine;
3-[1-(5-phenylethyl-thiophene-2-carbonyl)-piperidin-4-yl]-benzylamine;
4-fluoro-3-[1-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
4-methyl-3-[1-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
3-[1-(indole-6-carbonyl)-piperidin-4-yl]-benzylamine;
4-(3-aminomethyl-phenyl)-1-(5-phenethyl-pyridine-3-carbonyl)-piperidine-4-carbonitrile
[4-(3-aminomethylphenyl)piperidin-1-yl]-(3,4-dichlorophenyl)methanone;

1-{1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl}-3-methylsulfanyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-methylsulfanyl-6,7-dihydro-benzo[c]thiophen-1-yl)-methanone trifluoroacetate;
1-{1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl}-3-ethylsulfanyl-6,6-dimethyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
1-{1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl}-3-propylsulfanyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
1-{1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl}-3-isopropylsulfanyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-benzo[b]thiophen-2-yl-methanone-trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-4-hydroxy-piperidin-1-yl]-1-(5-phenethyl-pyridin-3-yl)-methanone-ditrifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(1-methyl-1H-indol-3-yl)-methanone-trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-[3-(2-fluoro-phenylethynyl)-phenyl]-methanone trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-{3-[2-(2-fluoro-phenyl)-ethyl]-phenyl}-methanone trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-{3-[2-(6-amino-pyridin-3-yl)-ethyl]-phenyl}-methanone tri-trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(6-chloro-thieno[3,2-b]thiophen-2-yl)-methanone trifluoroacetate;
(3R,4S) and (3S, 4R)-4-(3-Aminomethyl-phenyl)-1-(5-phenethyl-pyridine-3-carbonyl)-piperidine-3-carboxylic acid ethyl ester dihydrochloride;
3-[1-(5-Phenylethynyl-furan-2-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate;
4-(3-Aminomethyl-phenyl)-piperidine-1-carboxylic acid (3,4-dichloro-phenyl)-amide trifluoroacetate;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(2,3-dihydro-benzofuran-5-yl)-methanone;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(5,6-dichloro-pyridin-3-yl)-methanone;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-bromo-4-fluoro-phenyl)-methanone;
(E)-1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-3-(2-nitro-phenyl)-propenone;
1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-bromo-5-iodo-phenyl)-methanone; and
(E)-1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-3-phenyl-propenone.

53 51. (Currently Amended) A pharmaceutical composition comprising a ~~pharmaceutically~~ acceptable therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier thereof.

54 52. (Original) The pharmaceutical composition of Claim 51⁵³, wherein said compound is selected from the group consisting of:

- 3-[1-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
- 3-[1-(3-phenylethyl-benzoyl)-piperidin-4-yl]-benzylamine;
- 3-[1-[3-(4-hydroxyphenyl)ethyl-benzoyl]-piperidin-4-yl]-benzylamine;
- 3-[1-[3-(6-amino-pyridin-3-yl)ethyl-benzoyl]-piperidin-4-yl]-benzylamine;
- 3-[1-(5-phenylethyl-thiophene-2-carbonyl)-piperidin-4-yl]-benzylamine;
- 4-fluoro-3-[1-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
- 4-methyl-3-[1-(5-phenylethyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine;
- 3-[1-(indole-6-carbonyl)-piperidin-4-yl]-benzylamine;
- 4-(3-aminomethyl-phenyl)-1-(5-phenethyl-pyridine-3-carbonyl)-piperidine-4-carbonitrile
- [4-(3-aminomethylphenyl)piperidin-1-yl]-(3,4-dichlorophenyl)methanone;
- 1-[1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl]-3-methylsulfanyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
- 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-methylsulfanyl-6,7-dihydro-benzo[c]thiophen-1-yl)-methanone trifluoroacetate;
- 1-[1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl]-3-ethylsulfanyl-6,6-dimethyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
- 1-[1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl]-3-propylsulfanyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
- 1-[1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-methanoyl]-3-isopropylsulfanyl-6,7-dihydro-5H-benzo[c]thiophen-4-one trifluoroacetate;
- 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-benzo[b]thiophen-2-yl-methanone-trifluoroacetate;
- 1-[4-(3-Aminomethyl-phenyl)-4-hydroxy-piperidin-1-yl]-1-(5-phenethyl-pyridin-3-yl)-methanone-ditrifluoroacetate;
- 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(1-methyl-1H-indol-3-yl)-methanone-trifluoroacetate;
- 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-[3-(2-fluoro-phenylethynyl)-phenyl]-methanone trifluoroacetate;

1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-[3-[2-(2-fluoro-phenyl)-ethyl]-phenyl]-methanone trifluoroacetate;
 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-[3-[2-(6-amino-pyridin-3-yl)-ethyl]-phenyl]-methanone tri-trifluoroacetate;
 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(6-chloro-thieno[3,2-*b*]thiophen-2-yl)-methanone trifluoroacetate;
 (3*R*,4*S*) and (3*S*, 4*R*)-4-(3-Aminomethyl-phenyl)-1-(5-phenethyl-pyridine-3-carbonyl)-piperidine-3-carboxylic acid ethyl ester dihydrochloride;
 3-[1-(5-Phenylethynyl-furan-2-carbonyl)-piperidin-4-yl]-benzylamine trifluoroacetate;
 4-(3-Aminomethyl-phenyl)-piperidine-1-carboxylic acid (3,4-dichloro-phenyl)-amide trifluoroacetate;
 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(2,3-dihydro-benzofuran-5-yl)-methanone;
 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(5,6-dichloro-pyridin-3-yl)-methanone;
 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-bromo-4-fluoro-phenyl)-methanone;
 (E)-1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-3-(2-nitro-phenyl)-propenone;
 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-1-(3-bromo-5-iodo-phenyl)-methanone;
 (E)-1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-3-phenyl-propenone; and
 1-[4-(3-Aminomethyl-phenyl)-piperidin-1-yl]-3-cyclohexyl-propan-1-one.

55 53. (Currently Amended) A pharmaceutical composition comprising a ~~pharmaceutically~~
~~acceptable therapeutically effective~~ amount of a compound of Claim 21¹⁹ and a
 pharmaceutically acceptable carrier thereof.

56 54. (Currently Amended) A pharmaceutical composition comprising a ~~pharmaceutically~~
~~acceptable therapeutically effective~~ amount of a compound of Claim 36³⁷ and a
 pharmaceutically acceptable carrier thereof.

57 55. (Currently Amended) A method for treating asthma in a patient ~~comprises~~
~~comprising~~ administering to the patient a ~~pharmaceutically therapeutically~~ effective amount
 of a compound of Claim 1.

56. (Cancelled)

57. (Cancelled)

58. (Currently Amended) A method for treating asthma in a patient ~~comprises~~
comprising administering to the patient a pharmaceutically therapeutically effective amount
of a compound of Claim ~~21~~.¹⁹

59. (Cancelled)

60. (Cancelled)

59 ~~61~~. (Currently Amended) A method for treating asthma in a patient ~~comprises~~
comprising administering to the patient a pharmaceutically therapeutically effective amount
of a compound of Claim ~~26~~.³⁷

62. (Cancelled)

63. (Cancelled)

64. (Withdrawn) A pharmaceutical composition comprising a compound of Claim 1 and
a second compound selected from the group consisting of a beta andrenergic agonist, an
anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent; and a
pharmaceutically acceptable carrier thereof.

65. (Withdrawn) The pharmaceutical composition of Claim 64, wherein the beta
andrenergic agonist comprises albuterol, terbutaline, formoterol, fenoterol or prenaline;
the anticholinergic comprises ipratropium bromide;
the anti-inflammatory corticosteroid comprises beclomethasone dipropionate, triamcinolone
acetonide, flunisolide or dexamethasone; and
the anti-inflammatory agent comprises sodium cromoglycate or nedocromil sodium.

66. (Withdrawn) A pharmaceutical composition comprising a compound of formula 21
and a second compound selected from the group consisting of a beta andrenergic agonist, an
anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent; and a
pharmaceutically acceptable carrier thereof.

67. (Withdrawn) The pharmaceutical composition of Claim 66, wherein the beta
andrenergic agonist comprises albuterol, terbutaline, formoterol, fenoterol or prenaline;

the anticholinergic comprises ipratropium bromide;
the anti-inflammatory corticosteroid comprises beclomethasone dipropionate, triamcinolone acetonide, flunisolide or dexamethasone; and
the anti-inflammatory agent comprises sodium cromoglycate or nedocromil sodium.

68. (Withdrawn) A pharmaceutical composition comprising a compound Claim 36 and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent; and a pharmaceutically acceptable carrier thereof.

69. (Withdrawn) The pharmaceutical composition of Claim 66, wherein the beta andrenergic agonist comprises albuterol, terbutaline, formoterol, fenoterol or prenaline;
the anticholinergic comprises ipratropium bromide;
the anti-inflammatory corticosteroid comprises beclomethasone dipropionate, triamcinolone acetonide, flunisolide or dexamethasone; and
the anti-inflammatory agent comprises sodium cromoglycate or nedocromil sodium.

70. (Withdrawn) A method for treating a patient suffering from asthma, comprising administering to the patient a combination of a compound of Claim 1, and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent

71. (Withdrawn) A method for treating a patient suffering from asthma, comprising administering to the patient a combination of a compound of Claim 21, and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent.

72. (Withdrawn) A method for treating a patient suffering from asthma, comprising administering to the patient a combination of a compound of Claim 36, and a second compound selected from the group consisting of a beta andrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, and an anti-inflammatory agent.

24 73. (Previously Presented) The compound of Claim 23²³, wherein the phenylC₁₋₃alkylpyridyl is 5-phenylethyl-pyrid-3-yl, the phenylC₁₋₃alkylthienyl is and the indolyl is indol-6-yl.

²⁸
29 74. (Previously Presented) The compound of Claim 29, wherein the phenylC₁-alkylpyridyl is 5-phenylethyl-pyrid-3-yl, the phenylC₁-alkylthienyl is 5-phenylethyl-thien-2-yl and the indolyl is indol-6-yl.

36 75. (Previously Presented) The compound of Claim 35, wherein the phenylC₁-alkylpyridyl is 5-phenylethyl-pyrid-3-yl, the phenylC₁-alkylthienyl is 5-phenylethyl-thien-2-yl and the indolyl is indol-6-yl.

51 76. (Previously Presented) The compound of Claim 1, wherein is a single bond.